News Releases

August 2020

August 25, 2020 8/25/2020 Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

August 24, 2020 8/24/2020 Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion

August 7, 2020 8/7/2020 Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

August 3, 2020 8/3/2020 Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

August 3, 2020 8/3/2020 Announcement of a merger (simple merger/short-form merger) with a wholly owned subsidiary

July 2020

July 31, 2020 7/31/2020 Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

July 31, 2020 7/31/2020 Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit For The Full Year

July 30, 2020 7/30/2020 Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

July 11, 2020 7/11/2020 Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders